A Lecinoxoid, an oxidized phospholipid small molecule, constrains CNS autoimmune disease

Itzhak Mendel, Anat Shoham, Oshrat Propheta-Meiran, Eti Ishai, Gideon Halperin, Erez Feige, Eyal Breitbart

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

Oxidized phospholipids (Ox-PLs) are generated in abundance at sites of inflammation. Recent studies have indicated that Ox-PLs may also exhibit anti-inflammatory activities. In this study, we investigated the beneficial effect of VB-201, a pure synthetic Ox-PL analog that we synthesized, on the development of a central nervous system (CNS) autoimmune inflammatory disease, in vivo. Oral administration of VB-201 ameliorated the severity of experimental autoimmune encephalomyelitis (EAE) induced by myelin oligodendrocyte glycoprotein (MOG) peptide MOG35-55, and restrained the encephalogenicity of MOG35-55-specific T-cells. Our data presents a novel prospect for the role of Ox-PL analogs in CNS inflammatory diseases.

Original languageEnglish
Pages (from-to)126-135
Number of pages10
JournalJournal of Neuroimmunology
Volume226
Issue number1-2
DOIs
StatePublished - Sep 2010
Externally publishedYes

Keywords

  • Experimental autoimmune encephalomyelitis
  • Oxidized phospholipids
  • T-cells

Fingerprint

Dive into the research topics of 'A Lecinoxoid, an oxidized phospholipid small molecule, constrains CNS autoimmune disease'. Together they form a unique fingerprint.

Cite this